Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance

Frontiers in Genetics

Volumn 4, Issue MAR, 2013, Pages

  Zanger, Ulrich M ^a,b   Klein, Kathrin ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bupropion; Cyclophosphamide; Cytochrome P450; Drug metabolism; Drug drug interaction; Efavirenz; Pharmacogenetics; Pharmacogenomics

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84876078320     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00024     Document Type: Review

References (157)

1. Abass, K., and Pelkonen, O. (2012). The inhibition of major human hepatic cytochrome P450 enzymes by 18 pesticides: comparison of the N-in-one and single substrate approaches. Toxicol. In Vitro doi: 10.1016/j.tiv.2012.05.003 [Epub ahead of print].
2. Amunugama, H., Zhang, H., and Hol-lenberg, P. F. (2012). Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme. Drug Metab. Dispos. 40,1765-1770.
3. Ariyoshi, N., Miyazaki, M., Toide, K., Sawamura Yi, and Kamataki, T. (2001). A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 281, 1256-1260.
4. Ariyoshi, N., Ohara, M., Kaneko, M., Afuso, S., Kumamoto, T., Nakamura, H., et al. (2011). Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg2 62. Drug Metab. Dispos. 39, 2045-2048.
5. Asimus, S., and Ashton, M. (2009). Artemisinin - a possible CYP2B6 probe substrate? Biopharm. Drug Dispos. 30,265-275.
6. Bray, J., Sludden, J., Griffin, M. J., Cole, M., Verrill, M., Jamieson, D., et al. (2010). Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br. J. Cancer 102, 1003-1009.
7. Bumpus, N. N., and Hollenberg, P. F. (2008). Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity. Mol. Pharmacol. 74, 990-999.
8. Bumpus, N. N., Kent, U. M., and Hollenberg, P. F. (2006). Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J. Pharmacol. Exp. Ther. 318,345-351.
9. Bunten, H., Liang, W.-J., Pounder, D., Seneviratne, C., and Osselton, M. D. (2011). CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict. Biol. 16,142-144.
10. Burger, D., van der Heiden, I., la Porte, C., van der Ende, M., Groeneveld, P., Richter, C., et al. (2006). Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. 61, 148-154.
11. Burk, O., Arnold, K. A., Nussler, A. K., Schaeffeler, E., Efimova, E., Avery, B. A., et al. (2005). Anti-malarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67,1954-1965.
12. Chang, T. K., Weber, G. F., Crespi, C. L., and Waxman, D. J. (1993). Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver micro-somes. Cancer Res. 53,5629-5637.
13. Choudhary, D., Jansson, I., Schenkman, J. B., Sarfarazi, M., and Stoilov, I. (2003). Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. 414, 91-100.
14. Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, E J., Chang, T. K., and Waxman, D. J. (1997). Human cytochrome P4502B6: interindivid-ual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25, 985-993.
15. Cytochrome P-450 2B6 is responsible for interindivid-ual variability of propofol hydroxy-lation by human liver microsomes
16. Crane, A. L., Klein, K., and Olson, J. R. (2012). Bioactivation of chlorpyrifos by CYP2B6 variants. Xenobiotica 42, 1255-1262.
17. Crettol, S., Déglon, J.-J., Besson, J., Croquette-Krokkar, M., Gothuey, I., Hämmig, R., et al. (2005). Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin. Pharmacol. Ther. 78, 593-604.
18. Croom, E. L., Stevens, J. C., Hines, R. N., Wallace, A. D., and Hodgson, E. (2009). Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem. Pharmacol. 78, 184-190.
19. Das, P. C., Cao, Y., Rose, R. L., Cher-rington, N., and Hodgson, E. (2008). Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N,N-diethyl-m-toluamide (DEET). Drug Metab. Drug Interact. 23,237-260.
20. Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., et al. (2012). Stereose-lective and regiospecific hydroxyla-tion of ketamine and norketamine. Xenobiotica 42, 1076-1087
21. Desta, Z., Saussele, T., Ward, B., Bliever-nicht, J., Li, L., Klein, K., et al. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8, 547-558.
22. Dutheil, F., Beaune, P., and Loriot, M.-A. (2008). Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90, 426-436.
23. Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Déglon, J.-J., et al. (2007). Stereos-elective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metab-olizers. Clin. Pharmacol. Ther. 81, 719-728.
24. Ekhart, C., Doodeman, V. D., Roden-huis, S., Smits, P. H. M., Beijnen, J. H., and Huitema, A. D. R. (2008). Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharma-cokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet. Genomics 18, 515-523.
25. Ekins, S., Vandenbranden, M., Ring, B. J., Gillespie, J. S., Yang, T. J., Gelboin, H.V.,etal. (1998). Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286, 1253-1259.
26. Ekins, S., and Wrighton, S. A. (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31,719-754.
27. Ellison, C. A., Tian, Y., Knaak, J. B., Kostyniak, P. J., and Olson, J. R. (2012a). Human hepatic cytochrome p450-specific metabolism of the organophosphorus pesticides methyl parathion and diazinon. Drug Metab. Dispos. 40,1-5.
28. Ellison, C. A., Abou El-Ella, S. S., Taw-fik, M., Lein, P. J., and Olson, J. R. (2012b). Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J. Toxicol. Environ. Health A. 75, 232-241.
29. Erickson, D. A., Mather, G., Trager, W. E, Levy, R. H.,and Keirns, J. J. (1999). Characterization of the in vitro bio-transformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. DrugMetab. Dispos. 27, 1488-1495.
30. Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., et al. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28, 1222-1230.
31. Faucette, S. R., Wang, H., Hamilton, G. A., Jolley, S. L., Gilbert, D., Lind-ley, C., et al. (2004). Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab. Dispos. 32, 348-358.
32. Faucette, S. R., Zhang, T.-C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., et al. (2007). Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320,72-80.
33. Feidt, D. M., Klein, K., Hofmann, U., Riedmaier, S., Knobeloch, D., Thasler, W E., et al. (2010). Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. DrugMetab. Dispos. 38, 1589-1597.
34. Ferguson, C. S., and Tyndale, R. F. (2011). Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol. Sci. 32, 708-714.
35. Fuhr, U., Jetter, A., and Kirchheiner, J. (2007). Appropriate phenotyp-ing procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin. Pharmacol. Ther. 81,270-283.
36. Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., et al. (2007). Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45, 1230-1237.
37. Gatanaga, H., and Oka, S. (2009). Successful genotype-tailored treatment with small-dose efavirenz. AIDS 23, 433-434.
38. Gay, S. C., Shah, M. B., Talakad, J. C., Maekawa, K., Roberts, A. G., Wil-derman, P. R., et al. (2010). Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl) imida-zole at 2.0-A resolution. Mol. Pharmacol. 77, 529-538.
39. Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., et al. (1999). Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9,295-306.
40. Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., et al. (2009). Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10, 579-599.
41. Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., and Kliewer, S. A. (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60, 427-431.
42. Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18, 2391-2400.
43. Habtewold, A., Amogne, W., Makon-nen, E., Yimer, G., Riedel, K.-D., Ueda, N., et al. (2011). Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononu-clear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J. Antimicrob. Chemother. 66,2350-2361.
44. Harleton, E., Webster, M., Bum-pus, N. N., Kent, U. M., Rae, J. M., and Hollenberg, P. E (2004). Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J. Pharmacol. Exp. Ther. 310,1011-1019.
45. Helsby, N., and Tingle, M. (2011). The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status. Am. J. Hematol. 86, 383-384; author reply 384.
46. Helsby, N. A., Hui, C.-Y., Goldthorpe, M. A., Coller, J. K., Soh, M. C., Gow, P. J., et al. (2010). The combined impact of CYP2C19 and CYP2B6 pharmaco-genetics on cyclophosphamide bioactivation. Br. J. Clin. Pharmacol. 70, 844-853.
47. Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., von Moltke, L. L., et al. (2004). Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14,225-238.
48. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28,1176-1183.
49. Hodgson, E., and Rose, R. L. (2007). The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol. Ther. 113,420-428.
50. Hoffman, S. M., Nelson, D. R., and Keeney, D. S. (2001). Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11, 687-698.
51. Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M., et al. (2008). Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol Exp. Ther. 325, 284-292.
52. Holzinger, E. R., Grady, B., Ritchie, M. D., Ribaudo, H. J., Acosta, E. P., Morse, G. D., et al. (2012). Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics 22, 858-867.
53. Honda, M., Muroi, Y., Tamaki, Y., Saigusa, D., Suzuki, N., Tomioka, Y., et al. (2011). Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab. Dispos. 39, 1860-1865.
54. Hsyu, P. H., Singh, A., Giargiari, T. D., Dunn, J. A., Ascher, J. A., and Johnston, J. A. (1997). Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol. 37, 737-743.
55. Huang, Z., Roy, P., and Waxman, D. J. (2000). Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 59, 961-972.
56. Huitema, A. D., Kerbusch, T., Tibben, M. M., Rodenhuis, S., and Bei-jnen, J. H. (2000). Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother. Pharmacol. 46, 119-127.
57. Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38, 27-28.
58. Jeong, S., Nguyen, P. D., and Desta, Z. (2009). Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob. Agents Chemother. 53, 541-551.
59. Jiang, F., Desta, Z., Shon, J.-H., Yeo, C.-W., Kim, H.-S., Liu, K.-H., et al. (2012). Effects of clopi-dogrel and itraconazole on the disposition of efavirenz and its hydroxyl-metabolites: exploration of a novel CYP2B6 phenotyping index. Br. I Clin. Pharmacol. 75, 244-253.
60. Jinno, H., Tanaka-Kagawa, T., Ohno, A., Makino, Y., Matsushima, E., Hanioka, N., et al. (2003). Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31,398-403.
61. Joy, M. S., La, M., Wang, J., Bridges, A. S., Hu, Y., Hogan, S. L., et al. (2012). Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br. J. Clin. Pharmacol. 74, 445-455.
62. Kharasch, E. D., Mitchell, D., Coles, R., and Blanco, R. (2008). Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob. Agents Chemother. 52,1663-1669.
63. King, J., and Aberg, J. A. (2008). Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 22, 1709-1717.
64. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichel-baum, M., et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15, 861-873.
65. Ko, J. W., Desta, Z., and Flockhart, D. A. (1998). Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab. Dispos. 26, 775-778.
66. Korhonen, L. E., Turpeinen, M., Rah-nasto, M., Wittekindt, C., Poso, A., Pelkonen, O., et al. (2007). New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br. J. Pharmacol. 150,932-942.
67. Kreth, K., Kovar, K., Schwab, M., and Zanger, U. M. (2000). Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol. 59, 1563-1571.
68. Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., et al. (2003). Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307, 906-922.
69. Lang, T., Klein, K., Fischer, J., Nüssler, A. K., Neuhaus, P., Hofmann, U., et al. (2001). Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11,399-415.
70. Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., et al. (2004). Multiple novel nonsynony-mous CYP2B6 gene polymorphisms in Caucasians: demonstration of phe-notypic null alleles. J. Pharmacol. Exp. Ther. 311,34-43.
71. Leclerc, J., Tournel, G., Courcot-Ngoubo Ngangue, E., Pottier, N., Lafitte, J.-J., Jaillard, S., et al. (2010). Profiling gene expression of whole cytochrome P450 super-family in human bronchial and peripheral lung tissues: differential expression in non-small cell lung cancers. Biochimie 92, 292-306.
72. Lehr, T., Yuan, J., Hall, D., Zimdahl-Gelling, H., Schaefer, H. G., Staab, A., et al. (2011). Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet. Genomics 21, 721-730.
73. Levran, O., Peles, E., Hamon, S., Ran-desi, M., Adelson, M., and Kreek, M. J. (2011). CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi: 10.1111/j.1369-1600.2011.00349.x. [Epub ahead of print].
74. Lewis, D. F., Lake, B. G., Dickins, M., Eddershaw, P. J., Tarbit, M. H., and Goldfarb, P. S. (1999). Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b 5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica 29,361-393.
75. Lewis, D. F. V., Lake, B. G., and Dickins, M. (2004). Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. Drug Metab. Drug Interact. 20, 111-142.
76. Li, H., Ferguson, S. S., and Wang, H. (2010). Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation. Mol. Pharmacol. 78, 704-713.
77. Li, J., Menard, V., Benish, R. L., Jurevic, R. J., Guillemette, C., Stoneking, M., et al. (2012). Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics 13, 555-570.
78. Lin, H. L., Zhang, H., and Hol-lenberg, P. F. (2009). Metabolic activation of mifepristone (RU486) by mammalian P450s and the mechanism-based inactivation of human CYP2B6. J. Pharmacol. Exp. Ther. 329, 26-37.
79. Liu, P., Foster, G., LaBadie, R. R., Gutierrez, M. J., and Sharma, A. (2008). Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J. Clin. Pharmacol. 48, 73-84.
80. Lubomirov, R., Colombo, S., di Iulio, J., Ledergerber, B., Martinez, R., Cavassini, M., et al. (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis. 203,246-257.
81. Lubomirov, R., di Iulio, J., Fayet, A., Colombo, S., Martinez, R., Marzolini, C.,et al. (2010).ADMEpharmacoge-netics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet. Genomics 20, 217-230.
82. Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., et al. (2009). Cytochrome P450 2B6 516G->T is associated with plasma concentrations of nevirapine at both 200mg twice daily and 400mg once daily in an ethnically diverse population. HIVMed. 10, 310-317.
83. Maimbo, M., Kiyotani, K., Mushi-roda, T., Masimirembwa, C., and Nakamura, Y (2011). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur. J. Clin. Pharmacol. 68,267-271.
84. Martis, S., Mei, H., Vijzelaar, R., Edel-mann, L., Desnick, R. J., and Scott, S. A. (2012). Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmacogenomics J. doi: 10.1038/tpj.2012.48 [Epub ahead of print].
85. Mehlotra, R. K., Bockarie, M. J., and Zimmerman, P. A. (2007). CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br. J. Clin. Pharmacol. 64,391-395.
86. Melanson, S. E. F., Stevenson, K., Kim, H., Antin, J. H., Court, M. H., Ho, V. T., et al. (2010). Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloab-lative hematopoietic stem cell transplantation. Am. J. Hematol. 85, 967-971.
87. Meyer, R. P., Gehlhaus, M., Knoth, R., and Volk, B. (2007). Expression and function of cytochrome p450 in brain drug metabolism. Curr. Drug Metab. 8,297-306.
88. Miksys, S., Lerman, C., Shields, P. G., Mash, D. C., and Tyndale, R. E (2003). Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharma-cology 45, 122-132.
89. Mo, S.-L., Liu, Y.-H., Duan, W., Wei, M. Q., Kanwar, J. R., and Zhou, S.-F. (2009). Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab. 10, 730-753.
90. Mukonzo, J. K., Röshammar, D., Waako, P., Andersson, M., Fuka-sawa, T., Milani, L., et al. (2009). A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharma-cokinetics in Ugandans. Br. J. Clin. Pharmacol. 68, 690-699.
91. Nakajima, M., Komagata, S., Fujiki, Y., Kanada, Y., Ebi, H., Itoh, K., et al. (2007). Genetic polymorphisms of CYP2B6 affect the pharmacokinet-ics/pharmacodynamics of cyclophos-phamide in Japanese cancer patients. Pharmacogenet. Genomics 17, 431-445.
92. Nelson, D. R., Zeldin, D. C., Hoffman, S. M. G., Maltais, L. J., Wain, H. M., and Nebert, D. W (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14, 1-18.
93. Ngaimisi, E., Mugusi, S., Minzi, O. M., Sasi, P., Riedel, K.-D., Suda, A., et al. (2010). Long-term efavirenz autoin-duction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 88, 676-684.
94. Nguyen, T.-A., Tychopoulos, M., Bichat, E, Zimmermann, C., Flinois, J.-P., Diry, M., et al. (2008). Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. Mol. Pharmacol. 73, 1122-1133.
95. Niu, R.-J., Zheng, Q.-C., Zhang, J.-L., and Zhang, H.-X. (2011). Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. J. Mol. Model. 17, 2839-2846.
96. Nyakutira, C, Roshammar, D., Chigutsa, E., Chonzi, P., Ashton, M., Nhachi, C., et al. (2008). High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365.
97. Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., Tanaka, K., et al. (2001). Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br. J. Clin. Pharmacol. 51,281-285.
98. Oscarson, M., Zanger, U. M., Rifki, O. F., Klein, K., Eichelbaum, M., and Meyer, U. A. (2006). Transcrip-tional profiling of genes induced in the livers of patients treated with car-bamazepine. Clin. Pharmacol. Ther. 80,440-456.
99. Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., and Raunio, H. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 82, 667-715.
100. Peltoniemi, M. A., Saari, T. I., Hagel-berg, N. M., Reponen, P., Turpeinen, M., Laine, K., et al. (2011). Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin. Pharmacol. Ther. 90,296-302.
101. Penzak, S. R., Kabuye, G., Mugyenyi, P., Mbamanya, F., Natarajan, V., Alfaro, R. M., et al. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIVMed. 8, 86-91.
102. Qin, W.-J., Zhang, W., Liu, Z.-Q., Chen, X.-P., Tan, Z.-R., Hu, D.-L., et al. (2012). Rapid clinical induction of bupropion hydroxylation by metami-zole in healthy Chinese men. Br. J. Clin. Pharmacol. 74, 999-1004.
103. Raccor, B. S., Claessens, A. J., Dinh, J. C., Park, J. R., Hawkins, D. S., Thomas, S. S., et al. (2012). Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab. Dispos. 40, 54-63.
104. Radloff, R., Gras, A., Zanger, U. M., Masquelier, C., Arumugam, K., Karasi, J. C., et al. (2013). Novel CYP2B6 enzyme variants in a Rwan-dese population: functional characterization and assessment of in silico prediction tools. Hum. Mutat. doi: 10.1002/humu.22295 [Epub ahead of print].
105. Rae, J. M., Soukhova, N. V., Flockhart, D. A., and Desta, Z. (2002). Tri-ethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab. Dispos. 30, 525-530.
106. Rakhmanina, N. Y., and van den Anker, J. N. (2010). Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6, 95-103.
107. Ramírez, J., Innocenti, F., Schuetz, E. G., Flockhart, D. A., Relling, M. V., Santucci, R., et al. (2004). CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver micro-somes. Drug Metab. Dispos. 32, 930-936.
108. Remmer, H., Schoene, B., and Fleis-chmann, R. A. (1973). Induction of the unspecific microsomal hydroxy-lase in the human liver. Drug Metab. Dispos. 1,224-230.
109. Restrepo, J. G., Martínez, C., García-Agúndez, G., Gaviria, E., Laguna, J. J., García-Martín, E., et al. (2011). Cytochrome P450 CYP2B6 genotypes and haplotypesin a Colombian population: identification of novel variant CYP2B6 alleles. Pharmaco-genet. Genomics 21, 773-778.
110. Ribaudo, H. J., Haas, D. W., Tierney, C., Kim, R. B., Wilkinson, G. R., Gulick, R. M., et al. (2006). Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. 42, 401-407.
111. Ribaudo, H. J., Liu, H., Schwab, M., Schaeffeler, E., Eichelbaum, M., Motsinger-Reif, A. A., et al. (2010). Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J. Infect. Dis. 202, 717-722.
112. Richter, T., Mürdter, T. E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., et al. (2004). Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308, 189-197.
113. Richter, T., Schwab, M., Eichelbaum, M., and Zanger, U. M. (2005). Inhibition of human CYP2B6 by N,N',N"-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem. Pharmacol. 69, 517-524.
114. Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., et al. (2007). Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81,557-566.
115. Roy, J.-N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J., et al. (2005). CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887.
116. Sadee, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer, R. A., et al. (2011). Pharma-cogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin. Pharmacol. Ther. 89, 355-365.
117. Saussele, T., Burk, O., Blievernicht, J. K., Klein, K., Nussler, A., Nussler, N., et al. (2007). Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin. Pharmacol. Ther. 82, 265-274.
118. Shah, M. B., Pascual, J., Zhang, Q., Stout, C. D., and Halpert, J. R. (2011). Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl) pyridine: insight into inhibitor binding and rearrangement of active site side chains. Mol. Pharmacol. 80,1047-1055.
119. Simonsson, U. S. H., Jansson, B., Hai, T. N., Huong, D. X., Tybring, G., and Ashton, M. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin. Pharmacol. Ther. 74, 32-43.
120. Singh, G., Saxena, N., Aggarwal, A., and Misra, R. (2007). Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythe-matosus. J. Rheumatol. 34, 731-733.
121. Smith, G. B. J., Bend, J. R., Bedard, L. L., Reid, K. R., Petsikas, D., and Massey, T. E. (2003). Biotransfor-mation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab. Dispos. 31, 1134-1141.
122. Sridar, C., Kenaan, C., and Hol-lenberg, P. E (2012). Inhibition of bupropion metabolism by selegi-line: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab. Dispos. 40, 2256-2266.
123. Stewart, J. J., Berkel, H. J., Parish, R. C., Simar, M. R., Syed, A., Boc-chini, J. A., et al. (2001). Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J. Clin. Pharmacol. 41, 770-778.
124. Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., and Negishi, M. (1999). The repressed nuclear receptor CARresponds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274, 6043-6046.
125. Svensson, U. S., and Ashton, M. (1999). Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol. 48,528-535.
126. Takada, K., Arefayene, M., Desta, Z., Yarboro, C. H., Boumpas, D. T., Balow, J. E., et al. (2004). Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50, 2202-2210.
127. Talakad, J. C., Kumar, S., and Halpert, J. R. (2009). Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab. Dispos. 37, 644-650.
128. Telenti, A., and Zanger, U. M. (2008). Pharmacogenetics of anti-HIV drugs. Annu. Rev. Pharmacol. Toxicol. 48, 227-256.
129. Thelen, K., and Dressman, J. B. (2009). Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol. 61, 541-558.
130. Torimoto, Y., and Kohgo, Y. (2008). [Cyclophosphamide and CYP2B6]. Gan To Kagaku Ryoho 35,1090-1093.
131. Totah, R. A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K., and Kharasch, E. D. (2008). Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiol-ogy 108, 363-374.
132. Turpeinen, M., Raunio, H., and Pelko-nen, O. (2006). The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab. 7,705-714.
133. Turpeinen, M., Tolonen, A., Uusitalo, J., Jalonen, J., Pelkonen, O., and Laine, K. (2005a). Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 77,553-559.
134. Turpeinen, M., Uusitalo, J., Jouko, U., Jalonen, J., Jorma, J., Pelkonen, O., et al. (2005b). Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 24, 123-132.
135. Turpeinen, M., and Zanger, U. M. (2012). Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol. Drug Interact. 27, 185-197.
136. Walsky, R. L., and Obach, R. S. (2007). A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab. Dispos. 35,2053-2059.
137. Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., et al. (2003). A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J. Biol. Chem. 278, 14146-14152.
138. Wang, J., Sönnerborg, A., Rane, A., Josephson, F., Lundgren, S., Ståhle, L., et al. (2006). Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16,191-198.
139. Wang, H., and Tompkins, L. M. (2008). CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 9, 598-610.
140. Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., and Desta, Z. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287-300.
141. Watanabe, T., Sakuyama, K., Sasaki, T., Ishii, Y., Ishikawa, M., Hirasawa, N., et al. (2010). Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet. Genomics 20,459-462.
142. Wilderman, P. R., and Halpert, J. R. (2012). Plasticity of CYP2B enzymes: structural and solution biophysical methods. Curr. Drug Metab. 13, 167-176.
143. Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., et al. (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66, 2092-2098.
144. Xie, H., Griskevicius, L., Ståhle, L., Hassan, Z., Yasar, U., Rane, A., et al. (2006). Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur. J. Pharm. Sci. 27, 54-61.
145. Xie, H.-J., Yasar, U., Lundgren, S., Griskevicius, L., Terelius, Y., Hassan, M., et al. (2003). Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 3, 53-61.
146. Xu, C., Ogburn, E. T., Guo, Y., and Desta, Z. (2012). Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. DrugMetab. Dispos. 40, 717-725.
147. Yamanaka, H., Nakajima, M., Fukami, T., Sakai, H., Nakamura, A., Katoh, M., et al. (2005). CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos. 33, 1811-1818.
148. Yamazaki, H., Inoue, K., Hashimoto, M., and Shimada, T. (1999). Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver micro-somes. Arch. Toxicol. 73, 65-70.
149. Yang, X., Zhang, B.,Molony, C., Chudin, E., Hao, K., Zhu, J., et al. (2010). Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 20, 1020-1036.
150. Yao, S., Barlow, W E., Albain, K. S., Choi, J.-Y., Zhao, H., Livingston, R. B., et al. (2010). Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin. Cancer Res. 16,6169-6176.
151. Yimer, G., Amogne, W., Habtewold, A., Makonnen, E., Ueda, N., Suda, A., et al. (2011). High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 12,499-506.
152. Yuan, J., Guo, S., Hall, D., Cammett, A. M., Jayadev, S., Distel, M., et al. (2011). Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25, 1271-1280.
153. Zanger, U. M., and Hofmann, M. H. (2008). Polymorphiccytochromes P450 CYP2B6 and CYP2D6: recent advances on single nucleotide polymorphisms affecting splicing. Acta Chim. Slov. 55, 38.
154. Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H., and Schwab, M. (2007). Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8, 743-759.
155. Zhang, H., Amunugama, H., Ney, S., Cooper, N., and Hollenberg, P. F. (2011a). Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cys-teinyl residue 475 and loss of heme. Mol. Pharmacol. 80, 839-847.
156. Zhang, H., Sridar, C., Kenaan, C., Amunugama, H., Ballou, D. P., and Hollenberg, P. F. (2011b). Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J. Pharmacol. Exp. Ther. 338, 803-809.
157. Zukunft, J., Lang, T., Richter, T., Hirsch-Ernst, K. I., Nussler, A. K., Klein, K., et al. (2005). A natural CYP2B6 TATA box polymorphism (-82T->C) leading to enhanced transcription and relocation of the transcriptional start site. Mol. Pharmacol. 67, 1772-1782.